Faruk AŞICIOĞLU, Ahmet BELCE, Pınar Y. ÇELİK

Piperazin türevlerinin kötüye kullanımı

Son yıllarda, piperazinden türetilen bazı maddelerin kötüye kullanıldığı, kötüye kullanımlarının tüm dünyada yaygınlaştığı, bazı olgularda bu maddelerle ilişkili ciddi toksisite ve hatta ölümler olduğu bildirilmektedir. Sunulan çalışma, bu piperazin türevlerinin ülkemizdeki kötüye kullanımını araştırmak üzere planlanmıştır. Bu amaçla, son bir yıllık dönemde Adli Tıp Kurumu 5. İhtisas Kurulu'na gönderilen piperazin türevleri ile ilgili dosyalar incelenerek, olay yeri, yakalanan piperazin türevi, varsa beraberinde yakalanan maddeler birlikte değerlendirilmiştir. Elde edilen veriler, bu piperazin türevlerinin kötüye kullanımının ülkemizde de yaygınlaştığını göstermektedir. Kötüye kullanılan piperazin türevlerinin genel özellikleri ve toksisiteleri ile bu konuda alınabilecek yasal önlemler makale içinde tartışılmaktadır.

The abuse of piperazine derivatives

Recently, it has been reported that some piperazine derivatives are abused which is common all-around the world, causing serious toxicity and even death in some cases. Present study has been designed to investigate the abuse of these piperazine derivatives in our country. With this purpose, the files related with piperazine derivatives sent to the 5th Specialty Board of The Council of Forensic Medicine in the last one year period have been evaluated regarding event place, captured piperazine derivative and other captured subtances. Obtained data showed that abuse of these piperazine derivatives increased in our country, as well. Common features and toxicity of piperazine derivatives abused and legal regulations related with this subject are discussed in this paper.

PDF

___

1.Brunton LL, Lazo JS, Parker KL, editors. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 11th ed. McGraw-Hill, 2006: 461-500.
2.Sweetman SC, editor. Martindale: The Complete Drug Reference. 33rd ed. The Pharmaceutical Press, 2002: 271-314.
3.Olson KR, editor. Poisoning & Drug Overdose. 4th ed. McGraw-Hill, 2004: 96-98.
4.Sweetman SC, editor. Martindale: The Complete Drug Reference. 33rd ed. The Pharmaceutical Press, 2002: 547.
5.Sweetman SC, editor. Martindale: The Complete Drug Reference. 33rd ed. The Pharmaceutical Press, 2002: 649-714.
6.Sweetman SC, editor. Martindale: The Complete Drug Reference. 33rd ed. The Pharmaceutical Press, 2002: 987.
7.Sweetman SC, editor. Martindale: The Complete Drug Reference. 33rd ed. The Pharmaceutical Press, 2002: 1662.
8.Budevari S, editor. The Merck Index. 11th ed. Merck & Co., Inc, 1989:114.
9.Budevari S, editor. The Merck Index. 11th ed. Merck & Co., Inc, 1989: 639.
10.Cecchetti V, Schiaffella F, Tabarrini O, Fravolini A. (1,4-Benzothiazinyloxy)alkylpiperazine derivatives as potential antihypertensive agents. Bioorg Med Chem Lett, 2000; 10(5): 465-8.
11.Austin H, Monasterio E. Acute psychosis following ingestion of 'Rapture'. Australas Psychiatry, 2004; 12(4):406-8.
12.de Boe, D, Bosman IJ, Hidvegi E, et al. Piperazine-like compaunds: a new group of designer drugs-of-abuse on the European market. Forensic Sci Int, 2001; 121(1-2):47-56.
13.Gee P, Richardson S, Woltersdorf W, Moore G. Toxic effects of BZP-based herbal party pills in humans: a prospective study in Christehurch, New Zealand. N Z Med J, 2005; 118(1227):U1784.
14.Balmelli C, Kupferschmidt H, Rentsch K, Schneemann Ml. [Fatal brain edema after ingestion of ecstasy and benzylpiperazine]. Dtsch Med Wochenschr, 2001; 126(28-29):809-11.
15.Wood DM, Dargan PI, Button J, Holt DW, Ovaska H, Ramsey J, Jones AL. Collapse, reported seizure and an unexpected pill. Lancet, 2007; 369(9571): 1490.
16.Budevari S, editor. The Merck Index. 11th ed. Merck & Co., Inc, 1989:1185.
17.Staack RF, Maurer HH. Metabolism of designer drugs of abuse. Curr Drug Metab, 2005; 6(3):259-74.
18.Cioli V, Corradino C, Piccinelli D, Rocchi MG, Valeri P. A comparative pharmacological study of trazodone, etoperidone and 1 - (m-chlorophenyl)piperazine. Pharmacol Res Commun, 1984; 16(1):85- 100.
19.Benfenati E, Caccia S, Delia Vedova F. 1 -(o-Methoxyphenyl)piperazine is a metabolite of drugs bearing a methoxyphenylpiperazine side-chain. J Pharm Pharmacol, 1987; 39(4):312-3.
20.Staack RF, Maurer HH. New designer drug 1 -(3,4-methylenedioxybenzyl) piperazine (MDBP): studies on its metabolism and toxicological detection in rat urine using gas chromatography/mass spectrometry. J Mass Spectrom, 2004; 39(3):255-61.
21.Nagase T, Hotta K, Morita S, Sakai K, Yamane M, Omote M, Mizusawa H. [Pharmacological effects of the novel dopamine uptake inhibitor 1 -[2-[bis(4-fluorophenyl)-methoxy]ethyl]-4-(3-phenylpropyl) piperazine dihydrochloride (I-893) on the central nervous system]. Nippon Yakurigaku Zasshi, 1991; 98(2):121 -41.
22.Maurer HH, Kraemer T, Springer D, Staack RF. Chemistry, pharmacology, toxicology, and hepatic metabolism of designer drugs of the amphetamine (ecstasy), piperazine, and pyrrolidinophenone types: a synopsis. Ther Drug Monit, 2004; 26(2):127-31.
23.Glennon RA. Central serotonin receptors as targets for drug research. J Med Chem, 1987; 30(1):1-12.
24.Baumann MH, Clark RD, Budzynski AG, Partilla JS, Blough BE, Rothman RB. N-substituted piperazines abused by humans mimic the molecular mechanism of 3,4-methylenedioxymethamphetamine (MDMA, or 'Ecstasy'). Neuropsychopharmacology, 2005; 30(3):550-60.
25.Pettibone DJ and Williams M. Serotonin-releasing effects of substituted piperazines in vitro. Biochem Pharmacol, 1984; 33(9):1531-5.
26.Auerbach SB, Rutter JJ, Juliano PJ. Substituted piperazine and indole compounds increase extracellular serotonin in rat diencephalon as determined by in vivo microdialysis. Neuropharmacology, 1991; 30(4):307-11.
27.http://www.nzdf.org.nz/files/File/Drug-Foundation-submission-on-bzp-reclassification-March2007.pdf
28.McCann UD, Eligulashvili V, Mertl M, Murphy DL, Ricaurte GA. Altered neuroendocrine and behavioral responses to m-chlorophenylpiperazine in 3,4-methylenedioxymethamphetamine (MDMA) users. Psychopharmacology, 1999; 147(1):56-65.
29.LecompteY, Evrard I, Arditti J. Metachlorophenyl piperazine (mCPP): a new designer drug. Therapy, 2006; 61(6): 523-30.
30.Tsutsumi H, Katagi M, Miki A, Shima N, KamataT, Nishikawa M, Nakajima K, Tsuchihashi H. Development of simultaneous gas chromatography-mass spectrometric and liquid chromatography-electrosprayionization mass spectrometric determination method for the new designer drugs, N-benzylpiperazine (BZP), 1 -(3-trifluoromethylphenyl)piperazine (TFMPP) and their main metabolites in urine. J Chromatogr B Analyt Technol Biomed Life Sci, 2005; 819(2):315-22.
31.Bishop SC, McCord BR, Gratz SR, Loeliger JR, Witkowski MR. Simultaneous separation of different types of amphetamine and piperazine designer drugs by capillary electrophoresis with a chiral selector. J Forensic Sci, 2005; 50(2):326-35,
32.http://www.ndp.govt.nz/legalpartypills/documents/eacd-report-bzp-april2004.pdf
33.Caccia S. N-dealkylation of arylpiperazine derivatives: disposition and metabolism of the 1 -aryl-piperazines formed. Curr Drug Metab, 2007; 8(6): 612-22.
34.htpp//www.deadiversion.usdoj.gov/fed_regs/sched_actions/2002.
35.Johnstone AC, Lea RA, Brennan KA, Schenk S, Kennedy MA, Fitzmaurice PS. Benzylpiperazine: a drug of abuse? J Psychopharmacol, 2007, s.1-7.

ISSN: 1018-5275
Başlangıç: 1985
Yayıncı: BAYT Yayıncılık

Arşiv